DK0486572T3 - Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf - Google Patents

Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf

Info

Publication number
DK0486572T3
DK0486572T3 DK90912329.1T DK90912329T DK0486572T3 DK 0486572 T3 DK0486572 T3 DK 0486572T3 DK 90912329 T DK90912329 T DK 90912329T DK 0486572 T3 DK0486572 T3 DK 0486572T3
Authority
DK
Denmark
Prior art keywords
csf
receptor
granulocyte
derivatives
stimulating factor
Prior art date
Application number
DK90912329.1T
Other languages
English (en)
Inventor
Nicholas Martin Gough
Donald Metcalf
Nicos Anthony Nicola
David Paul Gearing
Julie Ann King
Original Assignee
Amrad Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corp Ltd filed Critical Amrad Corp Ltd
Application granted granted Critical
Publication of DK0486572T3 publication Critical patent/DK0486572T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK90912329.1T 1989-08-11 1990-08-10 Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf DK0486572T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ574389 1989-08-11
AUPK001490 1990-05-08

Publications (1)

Publication Number Publication Date
DK0486572T3 true DK0486572T3 (da) 1998-05-04

Family

ID=25643733

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90912329.1T DK0486572T3 (da) 1989-08-11 1990-08-10 Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf

Country Status (10)

Country Link
US (2) US5726036A (da)
EP (1) EP0486572B1 (da)
JP (1) JP3267966B2 (da)
AT (1) ATE161883T1 (da)
AU (1) AU637133B2 (da)
CA (1) CA2064814C (da)
DE (1) DE69031914T2 (da)
DK (1) DK0486572T3 (da)
SG (1) SG59954A1 (da)
WO (1) WO1991002063A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
AU673858B2 (en) * 1992-10-09 1996-11-28 Amrad Operations Pty. Limited Monoclonal antibody
EP0673389A1 (en) * 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
ATE360689T1 (de) * 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
AU2074101A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
WO2005038055A1 (en) * 2003-09-22 2005-04-28 Nathaniel Tue Tran Multiplexing array techniques
ES2395839T3 (es) * 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
JP2013505968A (ja) * 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法
WO2013072901A2 (en) * 2011-11-17 2013-05-23 Btm Mazowsze Sp. Zo.O. Compositions and methods for treating glioma
ES2721159T3 (es) 2012-12-14 2019-07-29 Biontech Rna Pharmaceuticals Gmbh Antígenos asociados a tumor independientes de MHC novedosos
CA2969704C (en) 2014-12-05 2023-05-02 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5112961A (en) * 1990-07-18 1992-05-12 Schering Corporation Dna encoding subunits of a high affinity gm-csf receptor

Also Published As

Publication number Publication date
US6136957A (en) 2000-10-24
SG59954A1 (en) 1999-02-22
DE69031914T2 (de) 1998-07-30
AU637133B2 (en) 1993-05-20
EP0486572A1 (en) 1992-05-27
CA2064814C (en) 2004-06-08
WO1991002063A1 (en) 1991-02-21
US5726036A (en) 1998-03-10
AU6189690A (en) 1991-03-11
DE69031914D1 (de) 1998-02-12
CA2064814A1 (en) 1991-02-12
JPH04507344A (ja) 1992-12-24
EP0486572A4 (en) 1993-05-05
EP0486572B1 (en) 1998-01-07
JP3267966B2 (ja) 2002-03-25
ATE161883T1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
Wuyts et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties
Ruff-Jamison et al. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver.
Seckinger et al. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor
Banerjee et al. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain.
Wolf et al. Granulocyte chemotactic protein 2 acts via both IL‐8 receptors, CXCR1 and CXCR2
Walz et al. A novel cleavage product of β-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils
EP0486572A4 (en) Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
Iida et al. β2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis
LU91759I2 (fr) Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
Kuznetsov et al. 18 kDa microtubule‐associated protein: identification as a new light chain (LC‐3) of microtubule‐associated protein 1 (MAP‐1)
CA2177838A1 (en) A methodology for selecting superagonists, antagonists and superantagonists of human interleukin-6 based on receptor complex three dimensional modelling
May et al. On the multimeric nature of natural human interleukin-6
DK0673420T3 (da) Mammale receptorer for interleukin 10 (IL-10)
FI961251A0 (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
ATE366809T1 (de) Addressine der schleimhaut und der blutgefässe und ihre verwendung
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
Chin et al. Identification of a high-affinity receptor for interleukin 1 alpha and interleukin 1 beta on cultured human rheumatoid synovial cells.
ATE89566T1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.
EP0789076A3 (en) G protein coupled receptor proteins, their production and use
EP0822986B1 (en) Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds
Roth et al. Assembly map of the 50‐S subunit from Escherichia coli ribosomes, covering the proteins present in the first reconstitution intermediate particle
Bienkowski et al. Purification and characterization of interleukin 1 receptor level antagonist proteins from THP-1 cells.
DE3667061D1 (en) New protein isolated from blood, process for preparing said protein, antibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment
AHB Application shelved due to non-payment